Study about correlation of anti-neutrophil cytoplasmic antibodies and anticardiolipin antibodies with thromboangiitis obliterans

Abstract

Doctors often have difficulties in clinical diagnosis and clinical stage of thromboangiitis obliterans (TAO). Immunolesion was important in the initiation and progression of various kinds of vasculitis diseases, including TAO. Several kinds of immune complexes were developed by immunolesion, including anti-neutrophil cytoplasmic antibodies (ANCA) and anticardiolipin antibodies (ACA). Our aim was to determine if it is an effective way for clinical diagnosis and clinical stage of TAO by detection of the presence of ANCA and ACA in blood serum of patients with TAO and the relationship among the presence of ANCA, ACA and patients with different grades of TAO. Blood samples and clinical characteristics were collected from 38 patients with Rutherford grade I TAO, 30 patients with Rutherford grade II–III TAO, 75 patients with arteriosclerosis obliterans (ASO) and 65 healthy volunteers. Their serum samples were investigated for ANCA by indirect immunofluorescent (IIF), and for ACA and ANCA specificity antigens including reactivity to proteinase 3(PR3), myeloperoxidase (MPO), cathepsin G (CG), bactericidal/permesbility-increasing protein (BPI), elastase (HLE) and lactoferrin (LF) by enzyme linked immunosorbent assay (ELISA). (1) ANCA positive rate and titre were much higher in cases with Rutherford grade I TAO (52.6%, 20/38, 0.386 ± 0.458) and Rutherford grade II–III TAO (73.3%, 22/30, 0.847 ± 0.658) than those in cases with ASO (4%, 3/75, 0.011 ± 0.002) and healthy volunteers (0%,0/65, 0.010 ± 0.002) (P < 0.01). ANCA positive rate and titre were higher in cases with Rutherford grade II–III TAO (73.3%, 22/30, 0.847 ± 0.658) than those in cases with Rutherford grade I TAO (52.6%, 20/38, 0.386 ± 0.458) (P < 0.05). (2) ACA concentration was much higher in cases with Rutherford grade I TAO (270.13 ± 13.05 IU/mL) and Rutherford grade II–III TAO (279.33 ± 19.98 IU/mL) than that in cases with ASO (236.85 ± 17.32 IU/mL) and healthy volunteers (229.16 ± 15.55 IU/mL) (P < 0.05) respectively. (3) In 42 cases of ANCA-positive samples, there were 20 cases reacted with MPO, 14 cases reacted with LF, five cases reacted with HLE, five cases reacted with BPI and no one reacted with PR3 and CG. All cases were Rutherford grade II–III TAO. Our results indicate that ANCA, ANCA specificity antigens and ACA were detected susceptibly and availably in patients with TAO. Thus, detection of ANCA, ANCA specificity antigens and ACA was helpful for clinical diagnosis of TAO and detection of ANCA and ANCA specificity antigens was helpful for clinical staging of TAO. They are important assistance for clinical diagnosis and stage of TAO.

Keywords

Anti-neutrophil cytoplasmic antibodies (ANCA)anticardiolipid antibodies (ACA)thromboangiitis obliterans (TAO)

Get full access to this article

View all access options for this article.

References

Olin

Shih

. Thromboangiitis obliterans (Buerger's disease). Curr Opin Rheumatol 2006;18:18–24.

Cooper

Henderson

Ballman

A prospective, case-control study of tobacco dependence in thromboangiitis obliterans (Buerger's Disease). Angiology 2006;57:73–8.

Matteson

John

. Thromboangiitis obliterans (Buerger's disease). In: Stone

(ed) A Clinician's Pearls and Myths in Rheumatology 2010: London: Springer, pp. 317–23.

Fazeli

Rezaee

. A review on thromboangiitis obliterans pathophysiology: thrombosis and angiitis, which is to blame? Vascular 2011;19:141–53.

Puechal

Fiessinger

. Thromboangiitis obliterans or Buerger's disease:challenges for the rheumatologist. Rheumatology 2007;46:192–9.

Maslowski

McBane

Alexewicz

Antiphospholipid antibodies in thromboangiitis obliterans. Vasc Med 2002;4:259–64.

Halacheva

Manolova

Petkov

Study of anti-neutrophil cytoplasmic antibodies in patients with thromboangeitis obliterans. Scand J Immunol 1998;48:544–50.

Adar

Papa

Halpern

Cellular sensitivity to collagen in thromboangiitis obliterans. New Engl J Med 1983;308:1113–6.

Rutherford

Baker

Ernst

Recommended standards for reports dealing with lower extremity ischemia: revised version. Vasc Surg 1997;26:517–38.

10.

Bosch

Guilabert

Font

. Antineutrophil cytoplasmic antibodies. Lancet 2006;9533:404–18.

11.

Mukhtyar

Flossmann

Hellmich

Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008;67:1004–10.

12.

Sebastian

Voetsch

Stone

The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. J Rheumatol 2007;34:2446–50.

13.

Martinez-Berriotxoa

Ruiz-Irastorza

Egurbide

Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus 2007;16:810–6.

14.

Naess

Christiansen

Cannegieter

A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost 2006;4:44–9.

15.

Pereira de Godoy

Braile

Torres

CAA

. Compartment syndrome in patients with Buerger disease and anticardiolipin antibodies. South Med J 2008;101:748–9.

16.

Noel

. Antineutrophil cytoplasm antibodies (ANCA): description and immunopathological role. Ann Med Interne (Paris) 2000;15:178.

17.

Kallenberg

CGM

Heeringa

Stegeman

. Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2006;2:661–70.

18.

Savage

. Pathogenesis of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Clin Exp Immunol 2011;164(S1):23–6.

19.

Sehultz

Diego

. ANCA and systemic vasculitis; update of assays. Semin Arthritis Rheum 2000;29:267.

20.

Mulligan

McAuley

. Thrombosis and psychosis – possible association with the antiphospholipid syndrome and anticardiolipin antibodies. Ir Med J 2009;102:61.

21.

Douglas

Triplett

. Antiphospholipid Antibodies. Arch Pathol Lab Med 2002;126:1424–9.